L-Carnitine: the nutrient sold as a fat-loss injectable, and what its trials actually show

L-Carnitine is a small, water-soluble molecule built from the amino acids lysine and methionine. Chemically it is a quaternary ammonium compound, sometimes described as an amino-acid derivative or a vitamin-like nutrient, and it is not a peptide: there is no chain of amino acids joined by peptide bonds, and it is not digested the way peptides are. The body makes it in the liver and kidneys, stores most of it in skeletal muscle, and tops it up from food, with red meat the richest source, followed by other meat, fish and dairy. A mixed diet supplies a few hundred milligrams a day; people who eat no meat make what they need ^[2][7].

The name covers several products. Levocarnitine is the pharmaceutical name for the same molecule and is what appears on prescription packaging such as Carnitor. L-carnitine L-tartrate is a stable salt used in most oral supplements and in the sports-nutrition trials. Acetyl-L-carnitine (ALCAR) is a related ester in which an acetyl group is attached to the carnitine molecule; it is studied mainly for brain and nerve outcomes and behaves somewhat differently in the body, so trial results for one form should not be assumed to apply to the other. Propionyl-L-carnitine is another ester used in vascular research. This guide is about plain L-carnitine, the form in Carnitor and in the injectable vials sold online.

So what is L-carnitine doing on a peptide price comparison site? Peptide stores stock it alongside compounds they market for fat loss, typically as pre-dissolved vials labelled L-carnitine injection at 200 mg/mL, 500 mg/mL or 600 mg/mL, or as 1 g/5 mL ampoules. PepFinder lists it under Other compounds sold by peptide stores rather than as a research peptide, and compares vial listings per milligram where the label states the total mass. The point of this guide is to set out what the published trials actually found, so that a reader can judge the L-carnitine benefits claimed in listings against the evidence. If you are new to the category, our explainer on what research peptides are describes how it differs from a nutrient like this one.

Carnitine's established role is transport. Long-chain fatty acids cannot cross the inner mitochondrial membrane on their own; they are attached to carnitine by the enzyme carnitine palmitoyltransferase I, shuttled across as acylcarnitines, then released inside the mitochondrion for beta-oxidation. Carnitine also buffers the mitochondrial acetyl-CoA pool, forming acetylcarnitine when acetyl groups accumulate during hard exercise, which is thought to keep pyruvate dehydrogenase running and limit lactate build-up ^[1][4].

The logic behind fat-loss marketing follows from the first role: more carnitine, more fat into mitochondria, more fat burned. The difficulty is that muscle carnitine is not limited by supply in healthy people. Muscle takes carnitine up against a steep concentration gradient by a sodium-dependent transporter, and simply swallowing or injecting more does not raise muscle stores; the excess is excreted in urine. The Nottingham group led by Greenhaff and Stephens showed that muscle uptake can be driven by insulin, and that a rise in muscle carnitine content required 24 weeks of oral L-carnitine taken with a large carbohydrate load twice a day ^[1]. There is no published evidence that intramuscular or subcutaneous injection of L-carnitine raises muscle carnitine content in healthy adults, and the transporter argument suggests it would not without the same insulin stimulus.

In true carnitine deficiency the picture is different. People with inherited transporter defects, some metabolic disorders, or losses through haemodialysis have low plasma and tissue carnitine, impaired fat oxidation and, in severe cases, muscle weakness, cardiomyopathy and low blood sugar. Replacing carnitine in those patients is straightforward replacement therapy, and it is the reason levocarnitine is a licensed medicine ^[8].

Weight and body composition is the outcome buyers care about, and it has been reviewed twice. Pooyandjoo and colleagues pooled nine randomised controlled trials in 2016 and reported that adults taking carnitine lost on average roughly a kilogram more than controls, with a small reduction in body mass index; the effect was modest and heterogeneity between trials was substantial ^[6]. Talenezhad and colleagues updated the picture in 2020 with 37 randomised trials and found small average reductions in body weight, BMI and fat mass, with the benefit concentrated in overweight and obese participants and no clear effect on waist circumference or body fat percentage; their dose-response analysis suggested that increasing the dose beyond about 2 g a day did not add to the effect ^[5]. Taken together, the evidence supports a small, real average effect in people who are overweight, of the order of one kilogram, and no evidence for L-carnitine for weight loss in lean people ^[5][6].

Muscle fuel use is where the mechanistic work is strongest. In the Wall 2011 study, healthy men who took L-carnitine L-tartrate with carbohydrate twice a day for 24 weeks increased their muscle carnitine content by about a fifth, and during exercise they used less glycogen at moderate intensity and produced less lactate at high intensity, with a measurable improvement in work output in a performance trial; the control group, taking carbohydrate alone, gained fat mass over the same period while the carnitine group did not ^[1]. It is one study of 14 men, it took six months, and the effect depended on around 80 g of carbohydrate with each dose, which is not what most supplement users do.

Exercise recovery has a small literature of its own. Fielding and colleagues reviewed it in 2018 and concluded that L-carnitine supplementation, mostly at 2 to 4 g a day for a few weeks, reduced markers of muscle damage and soreness after eccentric exercise in several trials, with the more consistent findings in older adults and in people who trained less ^[4]. Recovery markers are not the same as performance, and the review is careful to say so.

Fatigue and cognition in the very old is a niche but well-conducted trial. Malaguarnera and colleagues randomised centenarians to 2 g of L-carnitine a day or placebo for six months and reported reductions in physical and mental fatigue scores, a gain in lean mass and a fall in fat mass, and an improvement in a cognitive screening score in the treated group ^[3]. The participants were frail people aged around a hundred, so the result says little about a 35-year-old buying a vial.

Haemodialysis is the one setting where intravenous carnitine has a proper trial base, because dialysis strips carnitine from the blood. The 2025 meta-analysis by Nabi and colleagues pooled randomised trials of L-carnitine in haemodialysis patients and reported improved measures of cardiac function, with an acceptable safety profile, in a population that is carnitine depleted to begin with ^[8]. This is hospital treatment of a deficiency state, given by clinicians through the dialysis line, and it is the closest thing in the literature to evidence for injected L-carnitine; it does not transfer to injecting it for fat loss.

The finding that runs the other way is Koeth and colleagues' 2013 paper in Nature Medicine. Gut bacteria convert dietary carnitine into trimethylamine, which the liver oxidises to trimethylamine-N-oxide, or TMAO. The study showed that omnivores produced far more TMAO from a carnitine challenge than vegans, that high plasma carnitine was associated with cardiovascular events in a large cohort only when TMAO was also high, and that carnitine feeding accelerated atherosclerosis in mice in a microbiota-dependent way ^[2]. Whether supplemental L-carnitine at 1 to 2 g a day raises cardiovascular risk in humans is not settled; the meta-analyses of weight-loss trials did not run long enough or measure the right outcomes to answer it ^[5][6].

Unlike most compounds on PepFinder, L-carnitine has a large human evidence base. The 37 randomised trials in the Talenezhad meta-analysis span healthy, overweight, diabetic and dialysis populations, oral doses from under a gram to several grams a day, and durations from a few weeks to a year, which is why its pooled effect is more trustworthy than any single study ^[5]. The Pooyandjoo review reached a compatible answer from nine trials four years earlier ^[6]. The recurring limitations are short follow-up, small samples in individual trials, and inconsistency in whether participants also dieted or exercised.

The mechanistic trials are smaller and cleaner. Wall 2011 is a controlled 24-week study with muscle biopsies, which is why it is cited so often despite having only 14 participants; it answers the narrow question of whether and how muscle carnitine can be raised in healthy men ^[1]. The recovery trials reviewed by Fielding are typically two to four weeks long in a few dozen people each ^[4]. The centenarian study is a single-centre randomised trial of a few dozen participants over six months ^[3].

The intravenous evidence comes almost entirely from renal medicine. The trials pooled by Nabi and colleagues gave levocarnitine into the dialysis circuit at the end of sessions, in patients whose deficiency had been documented, and measured cardiac function rather than body fat ^[8]. There are no randomised trials of L-carnitine injection for fat loss in healthy adults, and there is no trial of the intramuscular self-injection schedules that appear on store listings and forums. The human studies that exist do not test what the product is sold for.

These are the doses studies used; they are not recommendations, and PepFinder does not advise on protocols. Oral L-carnitine in the weight-loss trials ranged from around 500 mg to 4 g a day, and the 2020 dose-response analysis found no additional benefit above roughly 2 g a day ^[5]. The muscle-loading study used 2 g of L-carnitine L-tartrate, providing a little under 1.4 g of carnitine, taken twice a day with 80 g of carbohydrate for 24 weeks ^[1]. The centenarian trial used 2 g a day for six months ^[3]. Exercise recovery trials mostly used 2 to 4 g a day for two to four weeks ^[4]. Hathcock and Shao's risk assessment set an observed safe level of 2,000 mg a day for oral supplementation on the basis of the trial data available in 2006 ^[7].

Intravenous levocarnitine in haemodialysis trials was given by clinicians according to body weight after each dialysis session, in patients with measured deficiency, and the licensed product information for Carnitor sets out the dose ranges for deficiency states ^[8]. There is no published L-carnitine dosage for injection in healthy adults, so any figure on a store listing or forum is not derived from a trial. The vials sold online contain a solution at a stated concentration, not a freeze-dried powder, so our L-carnitine calculator is only useful for converting a concentration and volume into milligrams; it does not carry a reconstitution step for this compound and it does not suggest a dose.

Oral L-carnitine has a long safety record. Hathcock and Shao reviewed the clinical trial data and found no pattern of adverse effects at intakes of up to 2 g a day, which they set as the observed safe level; higher intakes were not shown to be harmful but had less data behind them ^[7]. The L-carnitine side effects reported across trials are mostly digestive: nausea, abdominal cramps, diarrhoea and, at higher doses, a fishy body odour caused by the same trimethylamine that the TMAO story turns on ^[2][7]. The weight-loss meta-analyses did not identify a signal of serious harm, though they were not designed to look for one ^[5][6].

TMAO is the safety question that remains open. Koeth and colleagues showed that carnitine from red meat or supplements is converted to TMAO by gut bacteria in meat-eaters, and that TMAO was linked to cardiovascular events in their cohort and to atherosclerosis in mice ^[2]. Whether that translates into harm from supplement doses over years is not known; it is a reason for caution in people with existing cardiovascular disease rather than a demonstrated risk in the general population, and it is a reason not to take the fat-burning framing at face value.

Injection adds risks that oral use does not carry. Any unlicensed injectable from a peptide store may not be sterile or endotoxin-free, may be stored and shipped without temperature control, and comes with no batch release testing; the tissue concentrations of a 500 mg/mL solution injected into muscle have not been studied for local reactions. In the one setting where intravenous carnitine is well studied, haemodialysis, it is given by staff in a unit with monitoring, and the 2025 meta-analysis reports it as safe in that context, not as a home product ^[8]. In carnitine deficiency it is likewise prescribed and monitored ^[8]. People with seizure disorders, kidney disease, or on certain medicines should treat a supplement that alters carnitine handling as something to raise with a clinician rather than a commodity.

United Kingdom: levocarnitine is a prescription-only medicine, marketed as Carnitor in oral and injectable forms, for primary and secondary carnitine deficiency. L-carnitine at oral doses is also a food supplement regulated under food law, sold in pharmacies, supermarkets and sports-nutrition shops, with no licence needed. An injectable sold to the public by a peptide store is neither: it is an unlicensed medicine being supplied without a prescription, and the seller, not the buyer, is the party breaking medicines law. Our legal status overview explains the general position for compounds in this category.

United States: levocarnitine is approved by the FDA, as tablets, oral solution and injection, for primary and secondary carnitine deficiency. Oral L-carnitine is a dietary supplement under the Dietary Supplement Health and Education Act and is sold freely. Injectable L-carnitine is a prescription drug, and compounding pharmacies supply it on prescription; a research-chemical store selling vials for fat loss without a prescription is operating outside that system. So is L-carnitine legal? As a supplement, yes; as a prescription medicine, only on prescription; as an unlicensed injectable sold for fat loss, no.

European Union: levocarnitine medicines are authorised nationally in member states, and L-carnitine is a permitted food supplement ingredient across the EU; claims about fat burning or weight loss on supplement labels are not among the authorised health claims, so a store making them is making an unauthorised claim. Australia: levocarnitine is a prescription medicine, oral L-carnitine appears in listed complementary medicines, and injectable products require a prescription. Canada: levocarnitine is an authorised prescription drug, and L-carnitine is a licensable natural health product ingredient at oral doses; injectables are prescription-only. The pattern is the same everywhere: oral supplement legal, injectable prescription-only, store-sold vials unlicensed.

Sport: L-carnitine is not on the WADA Prohibited List, so taking it orally is permitted in tested sport. Method M2.2 of the List prohibits intravenous infusions or injections of more than 100 mL per 12-hour period except in the course of hospital treatment, surgical procedures or clinical diagnostic investigations, which rules out large-volume carnitine infusions regardless of the substance being permitted ^[9]. Reported use of carnitine infusions by athletes has been the subject of past controversy and inquiries in athletics, which is worth knowing without reading anything more into it than that.

Injectable L-carnitine is sold pre-dissolved in water, not as a lyophilised powder, which makes it unlike almost everything else on a peptide store's shelf. There is nothing to reconstitute, so bacteriostatic water is not needed and adding it only dilutes the product; the concentration on the label is the concentration in the vial. The licensed injectable is stored at room temperature and protected from light, and single-dose ampoules are discarded after opening. A 10 mL multi-dose vial from a research supplier may or may not contain a preservative, and if it does not, repeated draws from it carry the contamination risk of any unpreserved solution.

Oral products are simpler. L-carnitine L-tartrate powder and capsules are stable at room temperature in a dry, closed container; the free base is hygroscopic and cakes if left open. Our peptide storage guide is written for freeze-dried peptides that degrade with heat and moisture, and most of it does not apply here, but the general points about keeping vials sealed, dated and out of sunlight do. A solution that has turned cloudy, developed particles, or been frozen in transit should not be injected.

The obvious comparison is with the GLP-1 class. Semaglutide, tirzepatide and retatrutide are genuine peptides that suppress appetite, and their licensed or late-stage trials show double-digit percentage weight loss over a year or more; the L-carnitine meta-analyses show about a kilogram ^[5][6]. They are not in the same category of effect, and they carry different risks: the GLP-1 peptides have well-characterised gastrointestinal and other side effects and need prescription and supervision, while oral L-carnitine is a supplement with a long safety record at 2 g a day ^[7]. Our overview of peptides for weight loss puts the whole category side by side.

The closer comparison is with the other non-GLP-1 compounds that stores group under fat loss. AOD-9604 is a growth hormone fragment whose human weight-loss trials were negative. MOTS-c is a mitochondrial peptide with rodent data and almost no human data. 5-Amino-1MQ and SLU-PP-332 are small molecules, not peptides, with animal data only. Against those, L-carnitine is unusual in having dozens of human trials and a meta-analytic answer, even if the answer is a modest one ^[5]. It is also unusual in being cheap and legal to take by mouth.

It sits alongside several other non-peptides that peptide stores stock. NAD+, glutathione and melatonin are, like carnitine, molecules the body makes, sold as injectables on the strength of mechanism rather than outcome trials. In each case the oral supplement is legal and inexpensive and the injectable is an unlicensed product, and in each case PepFinder lists the compound because stores sell it, not because it is a peptide. Readers weighing the L-carnitine injection listings against the alternatives should note that the one setting where injected carnitine has trial support is haemodialysis ^[8], which is not what any of these listings are for.

A typical listing reads L-Carnitine 500 mg/mL, 10 mL vial, or Carnitine 1 g/5 mL, 10 ampoules, or L-carnitine injection 200 mg/mL. The two numbers that matter are the concentration and the volume, because together they give the total mass in the vial: a 500 mg/mL 10 mL vial holds 5 g, a 600 mg/mL 10 mL vial holds 6 g, and a 1 g/5 mL ampoule holds 1 g. Where a listing states both, PepFinder converts the price to a cost per milligram and ranks stores on it; where a listing gives only a volume, or only a marketing phrase, we cannot, and the listing is shown without a per-mg figure. The same rule we apply to a peptide vial's stated milligrams applies here, and our methodology page explains how the comparison is built.

Per-milligram comparison is meaningful for carnitine in a way it is not for some peptides, because the compound is a defined, stable small molecule that is manufactured at pharmaceutical scale: there is no question of sequence, purity by HPLC or truncated chains, and a gram is a gram. The comparison is only as good as the label, though. A supplier's certificate of analysis for a carnitine solution should show identity and concentration, which are easy tests to run; our guides to reading a COA and third-party peptide testing explain what a genuine certificate looks like and what a copied one looks like. Sterility and endotoxin testing, which matter more for an injectable than assay does, are rarely reported by research suppliers at all.

The price context is worth stating plainly. Oral L-carnitine L-tartrate from a supermarket or sports-nutrition retailer costs a few pence per gram; the injectable vials sold as L-carnitine for sale on peptide stores cost many times that per gram, for a route of administration that has no trial evidence in healthy people and that carries the risks of an unlicensed injectable. Anyone deciding to buy L-carnitine should know that the trial evidence for the modest weight effect comes from oral dosing ^[5][6]. You can compare L-carnitine prices across the stores we track, read how peptide prices are set to see why per-mg costs vary so much between suppliers, and check any store you have not used before against how to spot a fake peptide supplier and our supplier directory. Because L-carnitine is not a peptide and is a licensed medicine elsewhere, a store that lists it as an L-carnitine peptide, or claims it is a research chemical with no human data, is telling you something about its own accuracy.